bioAffinity Technologies, Inc. Research and Development Expense
bioAffinity Technologies, Inc. (BIAF) reported Research and Development Expense of $361.57 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-07
- bioAffinity Technologies, Inc. research and development expense for the quarter ending 2026-06-30 was $361.57K, a 16.12% increase year-over-year.
- bioAffinity Technologies, Inc. research and development expense for the quarter ending 2026-03-31 was $349.71K, a 4.81% decline year-over-year.
- bioAffinity Technologies, Inc. research and development expense for the quarter ending 2025-12-31 was $374.01K, a 4.26% decline year-over-year.
- bioAffinity Technologies, Inc. research and development expense for the quarter ending 2025-09-30 was $330.59K, a 20.43% increase year-over-year.
- bioAffinity Technologies, Inc. research and development expense for fiscal 2025 was $1.38M, a 5.33% decline from fiscal 2024.
- bioAffinity Technologies, Inc. research and development expense for fiscal 2024 was $1.46M, a 0.46% decline from fiscal 2023.
- bioAffinity Technologies, Inc. research and development expense for fiscal 2023 was $1.47M, a 6.48% increase from fiscal 2022.
- bioAffinity Technologies, Inc. research and development expense for fiscal 2022 was $1.38M, a 36.84% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $361.57K 10-Q · filed 2026-08-07 | $711.28K 10-Q · filed 2026-08-07 | $1.09M derived: sum of 3 quarters · filed 2026-08-07 | $1.42M derived: sum of 4 quarters · filed 2026-08-07 | |
| 2026-03-31 | $349.71K 10-Q · filed 2026-05-11 | $723.72K derived: sum of 2 quarters · filed 2026-05-11 | $1.05M derived: sum of 3 quarters · filed 2026-05-11 | $1.37M derived: sum of 4 quarters · filed 2026-08-07 | |
| 2025-12-31 | $374.01K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $704.60K derived: sum of 2 quarters · filed 2026-03-16 | $1.02M derived: sum of 3 quarters · filed 2026-08-07 | $1.38M 10-K · filed 2026-03-16 | |
| 2025-09-30 | $330.59K 10-Q · filed 2025-11-14 | $641.96K derived: sum of 2 quarters · filed 2026-08-07 | $1.01M 10-Q · filed 2025-11-14 | $1.40M derived: sum of 4 quarters · filed 2026-08-07 | |
| 2025-06-30 | $311.37K 10-Q · filed 2026-08-07 | $678.76K 10-Q · filed 2026-08-07 | $1.07M derived: sum of 3 quarters · filed 2026-08-07 | $1.34M derived: sum of 4 quarters · filed 2026-08-07 | |
| 2025-03-31 | $367.39K 10-Q · filed 2026-05-11 | $758.04K derived: sum of 2 quarters · filed 2026-05-11 | $1.03M derived: sum of 3 quarters · filed 2026-05-11 | $1.43M derived: sum of 4 quarters · filed 2026-05-11 | |
| 2024-12-31 | $390.66K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $665.15K derived: sum of 2 quarters · filed 2026-03-16 | $1.07M derived: sum of 3 quarters · filed 2026-03-16 | $1.46M 10-K · filed 2026-03-16 | |
| 2024-09-30 | $274.50K 10-Q · filed 2025-11-14 | $676.93K derived: sum of 2 quarters · filed 2025-11-14 | $1.07M 10-Q · filed 2025-11-14 | $1.50M derived: sum of 4 quarters · filed 2025-11-14 | |
| 2024-06-30 | $402.43K 10-Q · filed 2025-08-14 | $796.07K 10-Q · filed 2025-08-14 | $1.23M derived: sum of 3 quarters · filed 2025-08-14 | $1.56M derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | $393.64K 10-Q · filed 2025-05-15 | $826.46K derived: sum of 2 quarters · filed 2025-05-15 | $1.16M derived: sum of 3 quarters · filed 2025-05-15 | $1.49M derived: sum of 4 quarters · filed 2025-05-15 | |
| 2023-12-31 | $432.82K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $763.19K derived: sum of 2 quarters · filed 2025-03-31 | $1.10M derived: sum of 3 quarters · filed 2025-03-31 | $1.47M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $330.38K 10-Q · filed 2024-11-14 | $665.50K derived: sum of 2 quarters · filed 2024-11-14 | $1.04M 10-Q · filed 2024-11-14 | $1.46M derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | $335.13K 10-Q · filed 2024-08-14 | $704.74K 10-Q · filed 2024-08-14 | $1.13M derived: sum of 3 quarters · filed 2024-08-14 | $1.45M derived: sum of 4 quarters · filed 2024-08-14 | |
| 2023-03-31 | $369.62K 10-Q · filed 2024-05-15 | $798.85K derived: sum of 2 quarters · filed 2024-05-15 | $1.12M derived: sum of 3 quarters · filed 2024-05-15 | $1.37M derived: sum of 4 quarters · filed 2024-05-15 | |
| 2022-12-31 | $429.24K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $748.98K derived: sum of 2 quarters · filed 2024-04-01 | $997.40K derived: sum of 3 quarters · filed 2024-04-01 | $1.38M 10-K · filed 2024-04-01 | $1.14M 10-K · filed 2023-03-31 |
| 2022-09-30 | $319.74K 10-Q · filed 2023-11-14 | $568.16K derived: sum of 2 quarters · filed 2023-11-14 | $949.39K 10-Q · filed 2023-11-14 | $977.81K derived: sum of 4 quarters · filed 2023-11-14 | |
| 2022-06-30 | $248.42K 10-Q · filed 2023-08-14 | $528.27K 10-Q · filed 2023-08-14 | $658.07K derived: sum of 3 quarters · filed 2023-08-14 | $988.84K derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | $279.85K 10-Q · filed 2023-05-15 | $409.65K derived: sum of 2 quarters · filed 2023-05-15 | $740.42K derived: sum of 3 quarters · filed 2023-05-15 | ||
| 2021-12-31 | $129.80K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $460.57K derived: sum of 2 quarters · filed 2023-03-31 | $1.01M 10-K · filed 2023-03-31 | ||
| 2021-09-30 | $330.77K 10-Q · filed 2022-11-14 | $877.67K 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |